Search

everythinglearnresearchcommunity

for

Search:↓

A 10-year-old girl with hair and eyelash loss showed significant regrowth after treatment.

Microneedling with triamcinolone helps hair regrowth in ophiasis alopecia areata.

Unani medicine may help treat a rare, hard-to-treat hair loss pattern in children.

Secukinumab can cause hair loss, which may improve after stopping the medication.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Early recognition and treatment of atypical alopecia areata in infants are crucial.

A patient with a rare chromosome condition also had a rare type of hair loss.

Platelet-rich plasma (PRP) injections successfully treated a woman's steroid-resistant hair loss, causing hair to regrow within a month.

Fexofenadine may help treat a difficult type of hair loss.

Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.

Recognizing rare hair loss patterns in young females can improve understanding and treatment.

The patient with total hair loss did not regrow hair despite treatment, indicating a poor outlook for this type of hair loss.

Alopecia Areata Incognita causes sudden hair loss in young females but usually has a better outcome than other types.

Certain factors like allergies, nail problems, and hair loss patterns can predict how well someone with patchy hair loss will respond to skin cream treatments.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Alopecia areata is unpredictable, with limited treatment effectiveness, especially in severe cases.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

The paper concludes that recognizing bitemporal alopecia areata is important for early treatment and preventing its progression.

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.

Juvenile alopecia areata is more severe and has a worse prognosis than maturity-onset alopecia areata.

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

Early high-dose steroid treatment helps prolong disease-free periods in severe alopecia areata.

Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.

Researchers identified a new hair loss pattern called "sisaipho type," where hair is lost across the scalp except around the edges.

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Alopecia areata mainly affects young people, often showing as patchy hair loss on the scalp.

A girl with Crohn's disease developed hair loss from her medication, which improved with treatment but later returned.